Medtronic plc (MDT)
2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead
Robotic surgery used to be fodder for science fiction movies. Not anymore.
2 Healthcare Dividend Stocks to Hold for the Long Haul
Investors looking for stocks to hold on to for a while might want to consider dividend-paying companies. Besides offering a regular stream of passive income, dividend stocks have generally outperformed their non-dividend peers over the long run.
Medtronic: Guidance Raised, Solid Dividend, Shares Still A Bargain
Medtronic remains a buy due to its attractive valuation and steady EPS growth, despite recent sector-wide selling pressure and modest losses. Q2 results beat Wall Street expectations, with revenue up 5% year-over-year, and management raised FY 2025 revenue and earnings estimates. Key risks include supply chain issues, competition, policy changes, and currency fluctuations, but MDT's free cash flow yield and technical support levels are strong.
Reasons to Retain Medtronic Stock in Your Portfolio Now
Investors continue to be optimistic about MDT due to its impressive international expansion. Yet, the dull macroeconomic scenario poses a concern to the company's margins.
MDT Stock May Gain Following the Positive Data From Optimize PRO Study
Medtronic announces new positive data for its Evolut TAVR from the Optimize PRO clinical research.
Should You Pick Medtronic Stock At $85?
Medtronic (NYSE: MDT) reported its Q2 fiscal 2025 results (fiscal ends in April) last week, with revenues and earnings exceeding the street estimates. The company reported revenue of $8.4 billion and adjusted earnings of $1.26 per share, compared to the consensus estimates of $8.3 billion and $1.25, respectively.
MDT Stock Gains From FDA Approval for Its InPen App
Medtronic receives an FDA nod for its InPen app, which will help launch the company's Smart MDI system.
Here's Why Medtronic (MDT) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medtronic: A Dividend Aristocrat Powering Up for 2025 and Beyond
Medtronic's NYSE: MDT share price is down significantly from its peak in 2021, providing investors a deep-value opportunity. The stock price is down because of the post-COVID correction and headwinds leading to sluggish growth, which are factors that will not last forever.
Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing
Medtronic plc reported Q2 earnings today, with revenues of $8.4bn, up 5% year-on-year, adjusted EPS of $1.26, supported by a dividend yielding 3.2%. Despite consistent mid-single-digit revenue growth and new product launches, Medtronic's share price remains flat due to unpredictable net income and modest innovation. CEO Geoff Martha highlighted strong performance and innovation in key fields such as diabetes and hypertension, but stopped short of providing specific long-term growth guidance, keeping market sentiment lukewarm.
Gold Moves Higher; Medtronic Posts Upbeat Results
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.
Medtronic plc (MDT) Q2 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT ) Q2 2025 Earnings Conference Call November 19, 2024 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Gary Corona - Interim CFO Brad Welnick - VP, IR Que Dallara - EVP and President, Diabetes Operating Unit Sean Salmon - EVP and President, Cardiovascular Portfolio Mike Marinaro - EVP and President, Medical Surgical Portfolio and Surgical Operating Unit Brett Wall - EVP and President, Neuroscience Conference Call Participants Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Pito Chickering - Deutsche Bank Anthony Petrone - Mizuho Securities Rich Newitter - Truist Securities Danielle Antalffy - UBS Joanne Wuensch - Citi Matt Miksic - Barclays Patrick Wood - Morgan Stanley Ryan Weispfenning Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations and I appreciate that you're joining us for our Fiscal '25 Second Quarter Video Earnings Webcast.
